Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E Monument, Suite 2-630, Baltimore, MD 21287, USA.
Lancet. 2010 Jun 12;375(9731):2073-81. doi: 10.1016/S0140-6736(10)60674-5. Epub 2010 May 17.
Substantial controversy surrounds the use of estimated glomerular filtration rate (eGFR) and albuminuria to define chronic kidney disease and assign its stages. We undertook a meta-analysis to assess the independent and combined associations of eGFR and albuminuria with mortality.
In this collaborative meta-analysis of general population cohorts, we pooled standardised data for all-cause and cardiovascular mortality from studies containing at least 1000 participants and baseline information about eGFR and urine albumin concentrations. Cox proportional hazards models were used to estimate hazard ratios (HRs) for all-cause and cardiovascular mortality associated with eGFR and albuminuria, adjusted for potential confounders.
The analysis included 105,872 participants (730,577 person-years) from 14 studies with urine albumin-to-creatinine ratio (ACR) measurements and 1,128,310 participants (4,732,110 person-years) from seven studies with urine protein dipstick measurements. In studies with ACR measurements, risk of mortality was unrelated to eGFR between 75 mL/min/1.73 m(2) and 105 mL/min/1.73 m(2) and increased at lower eGFRs. Compared with eGFR 95 mL/min/1.73 m(2), adjusted HRs for all-cause mortality were 1.18 (95% CI 1.05-1.32) for eGFR 60 mL/min/1.73 m(2), 1.57 (1.39-1.78) for 45 mL/min/1.73 m(2), and 3.14 (2.39-4.13) for 15 mL/min/1.73 m(2). ACR was associated with risk of mortality linearly on the log-log scale without threshold effects. Compared with ACR 0.6 mg/mmol, adjusted HRs for all-cause mortality were 1.20 (1.15-1.26) for ACR 1.1 mg/mmol, 1.63 (1.50-1.77) for 3.4 mg/mmol, and 2.22 (1.97-2.51) for 33.9 mg/mmol. eGFR and ACR were multiplicatively associated with risk of mortality without evidence of interaction. Similar findings were recorded for cardiovascular mortality and in studies with dipstick measurements.
eGFR less than 60 mL/min/1.73 m(2) and ACR 1.1 mg/mmol (10 mg/g) or more are independent predictors of mortality risk in the general population. This study provides quantitative data for use of both kidney measures for risk assessment and definition and staging of chronic kidney disease.
Kidney Disease: Improving Global Outcomes (KDIGO), US National Kidney Foundation, and Dutch Kidney Foundation.
肾小球滤过率(eGFR)和白蛋白尿用于定义慢性肾脏病并划分其阶段,这方面存在很大争议。我们进行了荟萃分析,以评估 eGFR 和白蛋白尿与死亡率的独立和联合关联。
在这项对一般人群队列的合作荟萃分析中,我们汇总了包含至少 1000 名参与者且基线 eGFR 和尿液白蛋白浓度信息的研究中所有原因和心血管死亡率的标准化数据。使用 Cox 比例风险模型来估计与 eGFR 和白蛋白尿相关的所有原因和心血管死亡率的风险比 (HR),并针对潜在混杂因素进行了调整。
该分析包括来自 14 项研究的 105872 名参与者(730577 人年),这些研究均进行了尿液白蛋白与肌酐比值 (ACR) 测量,来自 7 项研究的 1128310 名参与者(4732110 人年)进行了尿液蛋白试纸测量。在进行 ACR 测量的研究中,eGFR 在 75 mL/min/1.73 m²和 105 mL/min/1.73 m²之间与死亡率无关,而在较低的 eGFR 水平下,死亡率风险增加。与 eGFR 95 mL/min/1.73 m²相比,eGFR 60 mL/min/1.73 m²的所有原因死亡率的调整 HR 为 1.18(95%CI 1.05-1.32),eGFR 45 mL/min/1.73 m²的为 1.57(1.39-1.78),eGFR 15 mL/min/1.73 m²的为 3.14(2.39-4.13)。ACR 在对数-对数标度上与死亡率呈线性相关,没有阈值效应。与 ACR 0.6 mg/mmol 相比,所有原因死亡率的调整 HR 为 ACR 1.1 mg/mmol 时为 1.20(1.15-1.26),ACR 3.4 mg/mmol 时为 1.63(1.50-1.77),ACR 33.9 mg/mmol 时为 2.22(1.97-2.51)。eGFR 和 ACR 与死亡率风险呈乘法相关,没有证据表明存在相互作用。在心血管死亡率和使用试纸测量的研究中也记录到了类似的发现。
eGFR 低于 60 mL/min/1.73 m²和 ACR 1.1 mg/mmol(10 mg/g)或更高是一般人群死亡风险的独立预测因素。本研究提供了定量数据,可用于使用两种肾脏指标进行风险评估以及定义和分期慢性肾脏病。
肾脏疾病:改善全球结局组织(KDIGO)、美国国家肾脏基金会和荷兰肾脏基金会。